logo BDSP

Base documentaire


  1. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women.

    Article - En anglais

    Background Postmenopausal oestrogen therapy reduces the risk of osteoporosis and cardiovascular diseases but is associated with an increased risk of endometrial cancer.

    We have assessed the impact of a regimen of oestrogen with cyclic progestagen on risk of endometrial cancer for postmenopausal women.

    Methods We did a population-based case-control study of women aged 45-74 years in western Washington State, USA.

    Cases were identified from a regional cancer registry as having histologically confirmed endometrial cancer during 1985-91. 832 (72%) of 1154 eligible cases completed interviews.

    Controls were identified by random digit dialling, screened for intact uterus, frequency matched for age and county, and randomly assigned a reference date within 1985-91. interviews with 1114 (73%) of 1526 eligible controls were done.

    The women provided information about use of hormone replacement therapy, and reproductive and medical history before diagnosis date (cases) or reference date (controls).

    Findings Relative to women who had never used hormones (for>6 months), women who had taken unopposed oestrogen had a four-fold increase (95% CI 3.1-5.1) in risk of endometrial cancer.

    Women who used a combined therapy of oestrogen with cyclic progestagen (eg, medroxyprogesterone acetate) had a relative risk of 1.4 (1.0-1.9).

    Among women with fewer than 10 days of added progestagen per month, the relative risk was 3.1 (1.7-5. (...)

    Mots-clés Pascal : Traitement substitutif, Oestrogène, Progestatif, Postménopause, Tumeur maligne, Endomètre, Epidémiologie, Facteur risque, Complication, Traitement, Homme, Femelle, Toxicité, Etats Unis, Amérique du Nord, Amérique, Hormone, Appareil génital femelle pathologie, Utérus pathologie

    Mots-clés Pascal anglais : Replacement therapy, Estrogen, Progestagen, Postmenopause, Malignant tumor, Endometrium, Epidemiology, Risk factor, Complication, Treatment, Human, Female, Toxicity, United States, North America, America, Hormone, Female genital diseases, Uterine diseases

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0172533

    Code Inist : 002B02O. Création : 21/05/1997.